cover image: Intrathecal baclofen pump for spasticity

Premium

20.500.12592/jmkqfp

Intrathecal baclofen pump for spasticity

16 Aug 2005

The rate of treatment discontinuation due to intolerable adverse effects has generally been reported to range from 4% to 27%.(2) When baclofen is administered orally, only a small portion of the original dose crosses the blood brain barrier and enters the central nervous system (CNS) fluid, which is the site of drug action. [...] Summary of Findings • Level 2 evidence supports the effectiveness of intrathecal baclofen infusion for the short-term reduction of severe spasticity in patients who are unresponsive or cannot tolerate oral baclofen • Level 3 evidence supports the effectiveness of intrathecal baclofen for the long-term reduction of severe spasticity in patients who are unresponsive or cannot tolerate oral baclofen [...] The rate of treatment discontinuation due to intolerable adverse effects has generally been reported to range from 4% to 27%.(2) When baclofen is administered orally, only a small portion of the original dose crosses the blood brain barrier and enters the CNS fluid, which is the site of drug action. [...] The major indications for botulinum toxin include the relief of spasticity in the calves in children with hemiplegic CP (loss of movement and sensation in the right or left half of the body) and the calves, hamstrings and hip adductors in diplegics.(3). [...] Length of Treatment The length of time that the treatment will be administered depends upon the nature of the underlying disease.
health science and technology research medical research medicine morphine health care meta-analysis therapy cerebral palsy clinical medicine multiple sclerosis baclofen injections, spinal injury placebo health treatment health sciences medical drugs medical specialties diseases and conditions ms spinal cord injury botulinum toxin intrathecal administration oral baclofen brain injury antispasmodics spastic spasticity
Pages
94
Published in
Canada

Related Topics

All